ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Warszawa, Mazowieckie

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Neoplasm Metastasis
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near Warszawa, Mazowieckie, POL:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Warsaw, Poland and 73 other locations

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Warszawa, Poland and 161 other locations

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily o...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis (RRMS)
Drug: Placebo
Drug: IMU-838 (10 mg/day)

Phase 2

Immunic Therapeutics

Warszawa, Poland and 37 other locations

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Enrolling
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Warsaw, Poland and 36 other locations

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Warszawa, Poland and 76 other locations

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.

(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...

Enrolling
Multiple Sclerosis
Drug: RO7121932 - MAD
Drug: RO7121932 SC - SAD

Phase 1

Roche
Roche

Warszawa, Poland and 23 other locations

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (LemKids)

effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...

Active, not recruiting
Multiple Sclerosis
Drug: Dexchlorpheniramine
Drug: Methylprednisolone

Phase 3

Genzyme
Genzyme

Warszawa, Poland and 20 other locations

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Drug: Ocrelizumab

Phase 3

Roche
Roche

Warszawa, Poland and 121 other locations

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CONNECT)

The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: dimethyl fumarate
Drug: Interferon β-1a

Phase 3

Biogen
Biogen

Warszawa, Poland and 61 other locations

Status recently updated

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...

Active, not recruiting
Enrolling
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Warszawa, Poland and 301 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems